Previous reports have demonstrated subjects with MTTP promoter -493G/T or I128T polymorphisms are susceptible to develop metabolic syndrome, hyperlipidemia, more oxidative stress, ischemic heart disease, β-cell dysfunction and non-alcoholic steatohepatitis [11–15]. This evidence concerns the gene MTTP and hyperlipidemia.